Envision Healthcare guidance likely conservative, says RBC Capital RBC Capital believes that Envision reported solid Q1 results. The firm thinks the company's guidance will prove to be conservative because it doesn't include benefits from health care reform. The firm keeps a $38 price target and Outperform rating on the shares.
BofA/Merrill healthcare high yield analyst has analyst/industry conference call Healthcare High Yield Analyst Bland provides an update on the current state of the bond markets and the ability of healthcare providers to utilize debt financing on an Analyst/Industry conference call to be held on March 24 at 10 am.
Envision Healthcare price target raised to $47 from $40 at Jefferies Jefferies raised its price target for Envision Healthcare shares to $47 and elevated the stock to a Top 5 Pick saying the recent exit of the company's private equity sponsor has eliminated a long-standing overhang. The firm also believes acquisition opportunities in physician services could drive EBITDA and share upside between now and year-end. It keeps a Buy rating on Envision.